|Trade names||Acofide (JP)|
|By mouth (tablets)|
|Metabolism||UGT1A8 and 1A9 (major)|
|Elimination half-life||10.9–21.7 hours|
|Excretion||Feces (92.7%), urine (5.3%)|
|Chemical and physical data|
|Molar mass||450.55 g/mol|
|3D model (JSmol)|
|(what is this?)|
Acotiamide (brand name Acofide, codenamed YM-443 and Z-338) is a drug manufactured and approved in Japan for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. It acts as an acetylcholinesterase inhibitor. It is pending approval in the United States; ten clinical trials have been successfully completed.
- "Acofide (acotiamide hydrochloride hydrate) Tablets Review Report" (PDF). Retrieved 29 December 2016.
- Matsueda, K; Hongo, M; Tack, J; Aoki, H; Saito, Y; Kato, H (June 2010). "Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients withfunctional dyspepsia – 100 mg t.i.d. is an optimal dosage". Neurogastroenterology & Motility. 22 (6): 618-e173. doi:10.1111/j.1365-2982.2009.01449.x. PMID 20059698.
|This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.|
|This article about an amine is a stub. You can help Wikipedia by expanding it.|